Last week, AstraZeneca admitted that the U.S. Justice Department is probing its controversial late-stage study of the blood thinner Brilinta. After a few days to digest that information, Bernstein's Tim Anderson has spelled out a worst-case scenario for the drug--and it's none too pretty. Worse, Brilinta is one of the products CEO Pascal Soriot hopes to transform into a growth engine for the company.
Bristol-Myers Squibb and Pfizer have hit another costly snag in their quest to gain an FDA approval for Eliquis (apixaban), their blockbuster anti-clotting hopeful.
An influential pharma analyst downgraded Merck shares, saying they've hit their price ceiling. Why? The reasons can be summed up in four drugs: Singulair, Gardasil, taranabant, and Vytorin. Sanford
Speculation that Bristol-Myers Squibb might be a takeover target-- that's old news. Informed speculation based on certain strategic moves BMS has made recently-- worth passing on. Tim Anderson, the